Another radiation restenosis treatment tested :
This article was originally published in Clinica
Executive Summary
Theragenics, a US company that makes the Theraseed prostate brachytherapy device, is to test its palladium-103 technology on animal models of coronary restenosis. The Buford, Georgia-based company has signed an agreement with the Atlanta Cardiovascular Research Institute to conduct a two-phase animal study, due to begin next month. The first phase will aim to determine whether a catheter-based Pd-103 source can inhibit restenosis, while the second will test stent-based Pd-103 devices. Theragenics is the latest in a long line of companies trying to exploit the anti-restenotic properties of various types of radiation sources.